Skip to main content
Fig. 3 | Surgical Case Reports

Fig. 3

From: Lung transplantation for idiopathic multicentric Castleman disease: potential efficacy and tolerability of a humanized anti-interleukin-6 receptor monoclonal antibody

Fig. 3

Postoperative course after lung transplantation. Tapering of triple immunosuppression (tacrolimus [TAC], mycophenolate mofetil [MMF], and prednisolone [PSL]) and sustained treatment with tocilizumab (TCZ) in an idiopathic multicentric Castleman disease transplant recipient. The interleukin-6 (IL-6) levels are maintained at 60–80 pg/mL, and the C-reactive protein (CRP) and procalcitonin (PCT) levels are trending towards normal with no allograft rejection

Back to article page